Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 4
1(33.3%)
N/A
1(33.3%)
3Total
Phase 2(1)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02728180Phase 4Unknown

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Role: collaborator

NCT03953885Not ApplicableUnknown

Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome

Role: collaborator

NCT03942198Phase 2Unknown

Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome

Role: collaborator

All 3 trials loaded